Amrita Krishnan

17.1k total citations · 2 hit papers
198 papers, 5.6k citations indexed

About

Amrita Krishnan is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Amrita Krishnan has authored 198 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Hematology, 113 papers in Oncology and 59 papers in Molecular Biology. Recurrent topics in Amrita Krishnan's work include Multiple Myeloma Research and Treatments (115 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and Lymphoma Diagnosis and Treatment (34 papers). Amrita Krishnan is often cited by papers focused on Multiple Myeloma Research and Treatments (115 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and Lymphoma Diagnosis and Treatment (34 papers). Amrita Krishnan collaborates with scholars based in United States, Spain and Netherlands. Amrita Krishnan's co-authors include Stephen J. Forman, Sagar Lonial, Arturo Molina, Auayporn Nademanee, John A. Zaia, Ajai Chari, Henry C. Fung, Ricardo Spielberger, Paul G. Richardson and Edward A. Stadtmauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Amrita Krishnan

192 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

2006 553 citations Amrita Krishnan, John P. Leonard et al. Journal of Clinical Oncology profile →
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2022 350 citations Ajai Chari, Jesús G. Berdeja et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amrita Krishnan United States	35	2.9k	2.8k	2.2k	1.1k	745	198	5.6k
Luciano J. Costa United States	35	3.2k 1.1×	2.4k 0.9×	1.9k 0.9×	614 0.5×	619 0.8×	256	4.8k
Christopher D. Gocke United States	39	1.3k 0.4×	2.0k 0.7×	2.2k 1.0×	1.2k 1.1×	707 0.9×	185	5.8k
Patrick J. Stiff United States	46	3.2k 1.1×	4.1k 1.5×	1.4k 0.6×	2.3k 2.1×	1.2k 1.7×	247	8.4k
Mark Kirschbaum United States	25	3.2k 1.1×	2.1k 0.7×	1.9k 0.9×	1.1k 1.0×	887 1.2×	66	6.2k
Robert Vescio United States	38	2.9k 1.0×	3.0k 1.1×	3.0k 1.4×	477 0.4×	591 0.8×	150	6.0k
Anthony S. Stein United States	43	3.9k 1.3×	2.9k 1.0×	1.5k 0.7×	873 0.8×	934 1.3×	242	6.8k
Ajay K. Nooka United States	36	3.5k 1.2×	3.4k 1.2×	2.9k 1.3×	578 0.5×	623 0.8×	282	6.0k
Donna Reece Canada	48	5.2k 1.8×	3.8k 1.4×	4.9k 2.2×	906 0.8×	1.1k 1.5×	349	8.2k
Graham Jackson United Kingdom	48	5.0k 1.7×	3.1k 1.1×	3.5k 1.6×	578 0.5×	786 1.1×	221	7.9k
Keith Stockerl‐Goldstein United States	36	3.3k 1.1×	1.8k 0.6×	1.7k 0.8×	588 0.5×	671 0.9×	200	5.2k

Countries citing papers authored by Amrita Krishnan

Since Specialization

Citations

This map shows the geographic impact of Amrita Krishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amrita Krishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amrita Krishnan more than expected).

Fields of papers citing papers by Amrita Krishnan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amrita Krishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amrita Krishnan. The network helps show where Amrita Krishnan may publish in the future.

Co-authorship network of co-authors of Amrita Krishnan

This figure shows the co-authorship network connecting the top 25 collaborators of Amrita Krishnan. A scholar is included among the top collaborators of Amrita Krishnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amrita Krishnan. Amrita Krishnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chari, Ajai, Susan Bal, Sikander Ailawadhi, et al.. (2025). Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(9). 635–645.

Touzeau, Cyrille, Meral Beksaç, Evangelos Terpos, et al.. (2024). Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology. 42(16_suppl). 7506–7506. 7 indexed citations

Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235.

Garfall, Alfred L., Ajay K. Nooka, Philippe Moreau, et al.. (2024). MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S548–S548. 8 indexed citations

Adhikarla, Vikram, Dennis Awuah, Enrico Caserta, et al.. (2024). Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma. Cancer Research. 84(6_Supplement). 7374–7374. 1 indexed citations

Malek, Ehsan, Leland Metheny, Pingfu Fu, et al.. (2024). Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplantation and Cellular Therapy. 30(7). 698.e1–698.e10. 1 indexed citations

Vescio, Robert, et al.. (2023). Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia. Blood. 142(Supplement 1). 7057–7057. 1 indexed citations

Sanchez, James F., Joycelynne Palmer, Timothy W. Synold, et al.. (2023). Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes. eScholarship (California Digital Library). 7(1). 9–27. 1 indexed citations

Adhikarla, Vikram, Dennis Awuah, Enrico Caserta, et al.. (2021). A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. Cancers. 13(20). 5171–5171. 12 indexed citations

10.

Shah, Nirav N., Amrita Krishnan, Nina Shah, et al.. (2019). Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. Blood. 134(Supplement_1). 5329–5329. 16 indexed citations

11.

Slavin, Thomas P., Jennifer Berano Teh, Jeffrey N. Weitzel, et al.. (2019). Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 25(12). 2517–2521. 18 indexed citations

12.

Bhella, Sita, Navneet S. Majhail, Luciano J. Costa, et al.. (2018). Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 24(5). 909–913. 31 indexed citations

13.

Wang, Xiuli, Miriam Walter, Ryan Urak, et al.. (2017). Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research. 24(1). 106–119. 149 indexed citations

14.

Façon, Thierry, Sagar Lonial, Brendan M. Weiss, et al.. (2017). Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001. Blood. 130. 1824–1824. 15 indexed citations

15.

Buettner, Ralf, Enrico Caserta, Domenico Viola, et al.. (2017). Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth. Blood. 130. 4426–4426. 2 indexed citations

16.

Rosenzweig, Michael, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2017). Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial. Blood. 130. 3144–3144.

17.

Chari, Ajai, Saad Z. Usmani, Amrita Krishnan, et al.. (2017). Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study. Blood. 130. 3110–3110. 23 indexed citations

18.

Gahrton, Gösta & Amrita Krishnan. (2013). Allogeneic transplantation in multiple myeloma. Expert Review of Hematology. 7(1). 79–90. 11 indexed citations

19.

Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2011). Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British Journal of Haematology. 153(6). 729–740. 78 indexed citations

20.

Krishnan, Amrita, John A. Zaia, & Arturo Molina. (2002). Stem Cell Transplantation and Gene Therapy for HIV-Related Lymphomas. Journal of Hematotherapy & Stem Cell Research. 11(5). 765–775. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact